NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)

ELOQUENT - 2

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

NCT01239797: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).

Sponsor: Bristol-Myers Squibb

Collaborator: AbbVie

Multiple Locations

International Study

ClinicalTrials.gov Identifier: NCT01239797

Official Title: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)

Click here for details on Clinicaltrials.gov

---

Elotuzumab : National Cancer Institute

Elotuzumab : MedlinePlus Drug Information

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

---

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.

Cancer. 2018 Oct 15

https://pubmed.ncbi.nlm.nih.gov/30204239/

An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.

AAPS J. 2017 Mar;19

https://pubmed.ncbi.nlm.nih.gov/28070715/

ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

N Engl J Med. 2015 Aug

https://pubmed.ncbi.nlm.nih.gov/26035255/

---

Drug: Lenalidomide

Drug: Dexamethasone

Drug: Dexamethasone (Oral)

Drug: Dexamethasone (IV)

Biological: Elotuzumab (BMS-901608; HuLuc63)

---

- Georgia: Emory University Atlanta

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Missouri: Washington University School of Medicine Saint Louis

- New York: NYU Langone Medical Center New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- North Carolina: Levine Cancer Institute Charlotte

- Texas: UT Southwestern Medical Center Dallas

- Texas: The University of Texas MD Anderson Cancer Center Houston